

Module 2.4: Non-Clinical Overview

Bimatoprost-Timolol/Pharmathen (0.3 mg/ml and 5 mg/ml) preservative free eye drops, solution in multi-dose container

Formulation of Pharmathen S.A.

Prepared by Dr.

B.Sc., M.Sc., Ph.D. in Clinical Medicine

Table of Contents

2.4 Non-Clinical Overview	4
2.4.1 Overview of the Non-clinical Testing Strategy	4
2.4.2 Pharmacology	5
Bimatoprost.....	5
Timolol.....	6
Rationale for combination therapy.....	7
2.4.2.1 Primary Pharmacodynamics	9
Bimatoprost.....	9
Secondary Pharmacodynamics	19
Timolol.....	21
Bimatoprost-Timolol Combination Activity.....	23
2.4.2.3 Pharmacodynamic Interactions	25
2.4.3 Pharmacokinetics	25
2.4.3.1. Analytical Methodology	25
2.4.3.2 Pharmacokinetics Overview	26
2.4.3.3. Absorption.....	26
2.4.3.4 Distribution	29
2.4.3.5 Metabolism	32
2.4.3.6. Excretion	35
2.4.4 Safety/Toxicology.....	36
2.4.4.1. Non-clinical toxicology	36
Bimatoprost.....	36
General toxicology.....	36
Toxicokinetics.....	36
Single Dose toxicity	36
Repeat dose toxicity	37
Reproductive toxicity.....	39
Genotoxicity.....	40
Immunotoxicity studies.....	40
Carcinogenicity	41
Fertility, pregnancy and lactation	41
Effects on ability to drive and use machines	42
Timolol.....	42
Acute toxicity.....	42

Chronic toxicity	42
Carcinogenicity	43
Genotoxicity.....	43
Reproductive toxicity	44
Lactation	44
Local toxicity studies	44
Effects on lens	46
Bimatoprost/Timolol Combination Toxicity Studies.....	46
2.4.4.2 Impurities and Excipients	47
2.4.4.3 Environmental risk assessment	48
2.4.4.4 Preservative Toxicity	48
2.4.5: Integrated Overview and Conclusions	51
2.4.6 REFERENCES	52

2.4 Non-Clinical Overview

2.4.1 Overview of the Non-clinical Testing Strategy

2.4.2 Pharmacology

Bimatoprost

Timolol

2.4.2.1 Primary Pharmacodynamics

Timolol

2.4.2.3 Pharmacodynamic Interactions

2.4.3 Pharmacokinetics

2.4.3.1. Analytical Methodology

2.4.3.2 Pharmacokinetics Overview

2.4.3.3. Absorption

2.4.3.4 Distribution

Bimatoprost-Timolol combination

2.4.3.5 Metabolism

Bimatoprost

In vitro metabolism

2.4.3.6. Excretion

2.4.4 Safety/Toxicology

2.4.4.1. Non-clinical toxicology

2.4.6 REFERENCES

AHFS drug information 2008a. McEvoy GK, ed. Timolol. Bethesda, MD: American Society of Health-System Pharmacists, 2008: 2930-2932.

AHFS drug information 2008b. McEvoy GK, ed. Timolol Maleate. Bethesda, MD: American Society of Health-System Pharmacists, 2008: 1922-1926.

Allemann R , Flammer J, Haefliger IO, 2003. Vasoactive properties of bimatoprost in isolated porcine ciliary arteries. *Klin Monbl Augenheilkd*; 220(3):161-4.

Ammar DA, Noecker RJ, Kahook MY, 2010. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia preserved topical glaucoma medications on human ocular epithelial cells. *Adv Ther*; 27(11):837-45.

Andrés-Guerrero V, Vicario-de-la-Torre M, Molina-Martínez IT, Benítez-del-Castillo JM, García-Feijoo J, Herrero-Vanrell R., 2011. Comparison of the in vitro tolerance and in vivo efficacy of traditional Timolol maleate eye drops versus new formulations with bio-adhesive polymers. *Invest Ophthalmol Vis Sci*: 52(6):3548-56.

Arnold JJ, Hansen MS, Gorman GS, Inoue T, Rao V, Spellens S, Hunsinger RN, Chapleau CA, Pozzo-Miller L, Stamer WD, Challa P, 2013. The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate. *Invest Ophthalmol Vis Sci*; 54(2):1118-26.

Ayaki M, and Iwasawa A, 2011. Cell viability of four corneoconjunctival cell lines exposed to five preservatives and a surfactant used for infection control in eye drops. *Biocontrol Sci*. 16: 117–121.

Barabino S, Antonelli S, Cimbolini N, Mauro V, Bouzin M, 2014. The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye. *Invest Ophthalmol Vis Sci*; 55(10):6499-504.

Bartoe JT, Davidson HJ, Horton MT, Jung Y, Brightman AH, 2005. The effects of bimatoprost and unoprostone isopropyl on the intraocular pressure of normal cats. *Vet Ophthalmol*; 8(4):247-52.

Baudouin C, Riancho L, Warnet JM, Brignole F, 2007. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. *Invest Ophthalmol Vis Sci*; 48(9):4123-8.

Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F, 2010. Preservatives in eye drops: the good, the bad and the ugly. *Prog Retin Eye Res*; 29(4):312–334.

Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I, 2008. Ganfort Investigators Group II. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. *J Glaucoma*; 17(3):211–216.

Brignole-Baudouin F, Riancho L, Liang H, Baudouin C, 2011. Comparative In Vitro Toxicology Study of Travoprost Polyquad-preserved, Travoprost BAK-preserved, and Latanoprost BAK-preserved Ophthalmic Solutions on Human Conjunctival Epithelial Cells. *Curr Eye Res*; 36(11):979-88.

Brubaker RF, 2001. Mechanism of action of bimatoprost (Lumigan). *Surv Ophthalmol*; 45 Suppl 4:S347-51.

Chen J, Senior J, Marshall K, Abbas F, Dinh H, Dinh T, Wheeler L, Woodward D, 2005. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. *Br J Pharmacol*; 144(4):493-501.

Chou A, Hori S, Takase M, 1985. Ocular toxicity of beta-blockers and benzalkonium chloride in pigmented rabbits: electrophysiological and morphological studies; *Jpn J Ophthalmol*, 29, 13-23.

Cohen JL, 2010. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. *Dermatol Surg*; 36: 1361–1371.

Coleman AL, Miglior S., 2008. Risk factors for glaucoma onset and progression. *Surv Ophthalmol*; 53:S3–10.

Dahlin DC, Bergamini MV W, Curtis MA, Dean TR, Kiehlbauch CC and Chastain JE, 2002. Bimatoprost Hydrolysis to 17-phenyl PGF₂{alpha} by Rabbit and Monkey Ocular Tissues, in vivo. *Invest Ophthalmol Vis Sci*; 43.

Davies SS, Ju WK, Neufeld AH, Abran D, Chemtob S, Roberts LJ 2nd, 2003. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. *J Ocul Pharmacol Ther*; 19(1):45-54.

DuoTrav®, SPC, 2015. Summary of Package Characteristics. Alcon Labs, Surrey, UK.

EGS Guidelines, 2014. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. Savona: PubliComm; p. 141.

Ellis PP, Wu PY, Riegel M, 1991. Aqueous humor pilocarpine and timolol levels after instillation of the single drug or in combination; *Invest Ophthalmol Vis Sci*, 32, 520-2.

EMA, 2009: EMA Public Statement on Antimicrobial Preservatives in Ophthalmic Preparations for Human Use (Doc. Ref.: EMA/622721/2009).

Frishman WH, Kowalski M, Nagnur S, Warshafsky S, Sica D, 2001. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of

glaucoma and ocular hypertension: focus on beta-adrenergic blockade; *Heart Dis*, 3, 386-97.

Fujino H, Pierce KL, Srinivasan D, Protzman CE, Krauss AH-P, Woodward DF, and Regan JW, 2000. Delayed reversal of shape change in cells expressing FPB prostanoid receptors. Possible role of receptor resensitization. *J Biol Chem*; 275: 29907–29914.

Furrer P, Berger J, Mayer JM, Gurny R, 2001. A comparative study of the ocular tolerance of 3 timolol-based preparations: the influence of preservatives on ocular tolerance; *J Fr Ophthalmol*, 24, 13-9.

Gagliuso DJ, Wang RF, Mittag TW, Podos SM, 2004. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. *Arch Ophthalmol*; 122(9):1342-7.

Gandolfi S, Simmons ST, Sturm R, Chen K, and VanDenburgh AM; Bimatoprost Study Group 3, 2001. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. *Adv Ther*; 18:110–121.

Ganfort® Scientific Discussion, 2006. EMA.

Gasset AR, 1977. Benzalkonium chloride toxicity to the human cornea. *Am J Ophthalmol*; 84(2):169–171.

Gatta L, Piscitelli F, Giordano C, Boccella S, Lichtman A, Maione S, and Di Marzo V, 2012. Discovery of prostamide F2a and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. *PLoS ONE*; 7:e31111

Gelatt KN, Mackay EO, 2002. Effect of different dose schedules of bimatoprost on intraocular pressure and pupil size in the glaucomatous Beagle. *J Ocul Pharmacol Ther*; 18(6):525-34.

Giannico AT, Lima L, Russ HH, Montiani-Ferreira F, 2013. Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits. *J Ocul Pharmacol Ther*; 29(9):817-20.

Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F, 2005. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. *Invest Ophthalmol Vis Sci*; 46(7):2444-50.

Hellberg MR, Ke TL, Haggard K, Klimko PG, Dean TR, Graff G, 2003. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF₂α by human and rabbit ocular tissue. *J Ocul Pharmacol Ther*; 19(2):97-103.

Higginbotham EJ, 2010. Considerations in glaucoma therapy: fixed combinations versus their component medications. *Clin Ophthalmol*; 4:1-9.

Holló G, 2007. The side effects of the prostaglandin analogues. *Expert Opin Drug Saf*; 6(1):45-52.

Inoue K, Shiokawa M, Sugahara M, Higa R, Wakakura M, and Tomita G, 2012. Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension. *Clin Ophthalmol*; 6: 111-116.

Izzotti A, La Maestra S, Micale RT, Longobardi MG, Saccà SC, 2015. Genomic and post-genomic effects of anti-glaucoma drugs preservatives in trabecular meshwork. *Mutat Res*; 772:1-9.

Kahook MY, Noecker RJ., 2008. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. *Adv Ther*; 25:743–51.

Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO, 2002. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol*; 120(6):701-13.

Khidhir K, Woodward DF, and Farjo N, 2013. A prostaglandin-related glaucoma therapy offers a novel approach for treating alopecia. *FASEB J*; 27: 557–567.

Khoh-Reiter S, Jessen BA, 2009. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. *BMC Ophthalmol*; 9:5.

Law SK, 2010. Bimatoprost in the treatment of eyelash hypotrichosis. *Clin Ophthalmol* 4:349–358.

Liang Y, Li C, Guzman VM, Evinger AJ, Protzman CE, Krauss AH-P, Woodward DF, 2003. Comparison of PGF2a, bimatoprost (prostamide) and butaprost (EP2 agonist) on Cyr 61 and CTGF gene expression. *J Biol Chem*; 278: 27267–27277.

Liang Y, Li C, Guzman VM, Chang WW, Evinger A, Pablo JV, Woodward DF, 2004. Upregulation of orphan nuclear receptor Nur 77 following PGF2a, bimatoprost and butaprost treatments. Essential role of a protein kinase C pathway involved in the EP2 receptor activated Nur 77 gene transcription. *Br J Pharmacol*; 142: 737–748.

Liang Y and Woodward DF, 2008. inventors, Allergan, Inc., assignee. Human prostaglandin FP receptor variants and methods of using same. U.S. patent 7320871. 2003 Jul 14.

Liang H, Brignole-Baudouin F, Pauly A, Riancho L, Baudouin C, 2011. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. *Adv Ther*; 28(4):311-25.

Liang H, Baudouin C, Labbe A, Riancho L, Brignole-Baudouin F., 2012. Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preserved in rabbit acute toxicity study. *PLoS One*; 7:e33913.

Liu HK, Chiou GC, Garg LC, 1980. Ocular hypotensive effects of timolol in cat eyes; *Arch Ophthalmol*, 98, 1467-9.

Lou H , Wang H, Zong Y, Cheng JW, Wei RL., 2015. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. *Curr Med Res Opin*; 31(6):1139-47.

Lumigan® Prescribing Info, 2014. LUMIGAN® (bimatoprost ophthalmic solution) 0.01% for topical ophthalmic use Prescribing Information. Allergan Inc, Irvine CA, USA.

Lumigan® Scientific Discussion, 2004. Lumigan Scientific Discussion, EMEA.

Matias I, Chen J, De Petrocellis L, Bisogno T, Ligresti A, Fezza F, Krauss AH, Shi L, Protzman CE, Li C, Liang Y, Nieves AL, Kedzie KM, Burk RM, Di Marzo V, Woodward DF, 2004. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. *J Pharmacol Exp Ther*; 309(2):745-57.

Maxey KM, Johnson JL, LaBrecque J, 2002. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. *Surv Ophthalmol*; 47 Suppl 1:S34-40.

Nagai N, Murao T, Okamoto N, Ito Y, 2010. Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium. *J Oleo Sci*; 59(3):135-41.

Nasir F, Iqbal Z, Khan A, Ahmad L, Shah Y, Khan AZ, Khan JA, Khan S., 2011. Simultaneous determination of timolol maleate, rosuvastatin calcium and diclofenac sodium in pharmaceuticals and physiological fluids using HPLC-UV. *J Chromatogr B Analyt Technol Biomed Life Sci*; 879(30):3434-43.

Noecker RJ, Herrygers LA, Anwaruddin R, 2004. Corneal and conjunctival changes caused by commonly used glaucoma medications. *Cornea*; 23(5):490-6.

Ogundele AB, Jasek MC, 2010. Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits. *Clin Ophthalmol*; 4:1447-50.

Okahara A, Tanioka H, Takada K, Kawazu K., 2013. Ocular toxicity of benzalkonium chloride homologs compared with their mixtures. *J Toxicol Pathol*; 26(4):343-9.

Olah Z, Veselovsky J, 2013. A decrease of the rabbit's physiologic IOP after the application of specific amino acids and double combination of antiglaucomatics mixture. *Bratisl Lek Listy*; 114(7):365-8.

Olthoff CM, Schoten JS, van de Borne BW, Webers CA., 2005. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. *Ophthalmology*; 112:953-61.

Ota T, Aihara M, Narumiya S, and Araaie M, 2005. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. *Invest Ophthalmol Vis Sci* 46:4159-4163.

Pisella PJ, Fillacier K, Elena PP, Debbasch C, Baudouin C, 2000. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits; *Ophthalmic Res*, 32, 3-8.

Potter DE, Nicholson HT, Rowland JM, 1982. Ocular hypertensive response to beta-adrenoceptor agonists; *Curr Eye Res*, 2, 711-9.

Richter M, Krauss AH, Woodward DF, Lütjen-Drecoll E, 2003. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. *Invest Ophthalmol Vis Sci*; 44(10):4419-26.

Sarkar J, Chaudhary S, Namavari A, Ozturk O, Chang JH, Yco L, Sonawane S, Khanolkar V, Hallak J, Jain S., 2012. Corneal neurotoxicity due to topical benzalkonium chloride. *Invest Ophthalmol Vis Sci*; 53(4):1792-802.

Schmid KL, Abbott M, Humphries M, Pyne K, Wildsoet CF, 2000. Timolol lowers intraocular pressure but does not inhibit the development of experimental myopia in chick; *Exp Eye Res*, 70, 659-66.

Schmitt CJ, Lotti VJ, LeDouarec JC, 1980. Penetration of timolol into the rabbit eye. Measurements after ocular instillation and intravenous injection; *Arch Ophthalmol*, 98, 547-51.

Shafaa MW, Sabra NM, Fouad RA, 2011. The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits. *Biopharm Drug Dispos*; 32(9):507-17.

Sharif NA, Williams GW, Kelly CR, 2001. Bimatoprost and its free acid are prostaglandin FP receptor agonists. *Eur J Pharmacol*; 432(2-3):211-3.

Sharif NA, Kelly CR, Crider JY, 2002. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. *J Ocul Pharmacol Ther*; 18(4):313-24.

Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX, 2003. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. *J Ocul Pharmacol Ther*; 19(6):501-15.

Silvestri C, Martella A, Poloso NJ, Piscitelli F, Capasso R, Izzo A, Woodward DF, and Di Marzo V, 2013. Anandamide-derived prostamide F2a negatively regulates adipogenesis. *J Biol Chem*; 288(32):23307-21.

Spada CS, Krauss AH, Woodward DF, Chen J, Protzman CE, Nieves AL, Wheeler LA, Scott DF, Sachs G, 2005. Bimatoprost and prostaglandin F(2alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. *Exp Eye Res*; 80(1):135-45.

Stamer WD, Piwnica D, Jolas T, Carling RW, Cornell CL, Fliri H, Martos J, Pettit SN, Wang JW, and Woodward DF, 2010. Cellular basis for bimatoprost effects on human conventional outflow. *Invest Ophthalmol Vis Sci*; 51:5176–5181.

Sugiyama T, Shibata M, Kajiura S, Okuno T, Tonari M, Oku H, Ikeda T, 2011. Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits. *Invest Ophthalmol Vis Sci*; 52(1):64-9.

Takano N, Tsuruma K, Ohno Y, Shimazawa M, Hara H, 2013. Bimatoprost protects retinal neuronal damage via Akt pathway. *Eur J Pharmacol*; 702(1-3):56-61.

Tan AY, LeVatte TL, Archibald ML, Tremblay F, Kelly ME, Chauhan BC, 2002. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing, *J Glaucoma*, 11, 134-42.

Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, Paus R, and Lütjen-Drecoll E, 2010. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost. *Br J Dermatol*; 162: 1186–1197.

Timolol maleate, Ph.Eur.monograph, 2014. 8.2 edition, EDQM, Strassburg, France.

Timoptol® SPC, 2014. Timolol Unit Dose, Merck Sharp & Dohme Limited, Hertfordshire, 2014.

Tripathi BJ, Tripathi RC, and Kolli SP, 1992. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. *Lens Eye Toxic Res.* 9: 361–375.

Uematsu M, Kumagami T, Shimoda K, Kusano M, Teshima M, To H, Kitahara T, Kitaoka T, Sasaki H, 2011. Polyoxyethylene hydrogenated castor oil modulates benzalkonium chloride toxicity: comparison of acute corneal barrier dysfunction induced by travoprost z and travoprost. *J Ocul Pharmacol Ther*; 27(5):437-44.

Vielhauer GA, Fujino H, and Regan JW, 2004. Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor. *Arch Biochem Biophys*; 421: 175–185.

Vila TO and Camacho Martinez FM, 2010. Bimatoprost in the treatment of eyelash universalis alopecia areata. *Int J Trichol* 2:86–88.

Volotinen M, Hakkola J, Pelkonen O, Vapaatalo H, Mäenpää J., 2011. Metabolism of ophthalmic timolol: new aspects of an old drug. *Basic Clin Pharmacol Toxicol*; 108(5):297-303.

Wan Z, Woodward DF, Cornell CL, Fliri HG, Martos JL, Pettit SN, Wang JW, Kharlamb AB, Wheeler LA, Garst ME, Landsverk KJ, Struble CS, Stamer WD, 2007. Bimatoprost, prostamide activity, and conventional drainage. *Invest Ophthalmol Vis Sci*; 48(9):4107-15.

Whitson JT, Cavanagh HD, Lakshman N, Petroll WM, 2006. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. *Adv Ther*; 23(5):663-71.

Whitson JT, Petroll WM., 2012. Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents. *Adv Ther*; 29:874–88.

Wilson SJ, Roche AM, Kostetskaia E, and Smyth EM, 2004. Dimerization of the human receptors for prostacyclin and thromboxane receptor-mediated cAMP generation. *J Biol Chem*; 279: 53036–53047.

Woodward DF, Lawrence RA, 1994. Identification of a single (FP) receptor associated with prostanoid-induced Ca²⁺ signals in Swiss 3T3 cells. *Biochem Pharmacol*; 47(9):1567-74.

Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, Chen R, Gil DW, Kharlamb A, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Weber A, Welty D, Yang W, Tang-Liu DD, Garst ME, Brar B, Wheeler LA, Kaplan LJ, 2001. The pharmacology of bimatoprost (Lumigan). *Surv Ophthalmol*; 45 Suppl 4:S337-45. Review. Erratum in: *Surv Ophthalmol* 2002 May-Jun;47(3):295.

Woodward DF, Krauss AH, Chen J, Liang Y, Li C, Protzman CE, Bogardus A, Chen R, Kedzie KM, Krauss HA, Gil DW, Kharlamb A, Wheeler LA, Babusis D, Welty D, Tang-Liu DD, Cherukury M, Andrews SW, Burk RM, Garst ME, 2003.

Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). *J Pharmacol Exp Ther*; 305(2):772-85.

Woodward DF, Phelps RL, Krauss AH, Weber A, Short B, Chen J, Liang Y, Wheeler LA, 2004. Bimatoprost: a novel antiglaucoma agent. *Cardiovasc Drug Rev*; 22(2):103-20.

Woodward DF, Krauss AH, and Nilsson SF, 2010. Bimatoprost effects on aqueous humor dynamics in monkeys. *J Ophthalmol*; 2010: 926192.

Wu PY, Riegel M, Ellis PP, 1989. High-performance liquid chromatographic assay for timolol in the aqueous humor of the eye; *J Chromatogr*, 29, 368-75.

Yamagishi R, Aihara M, and Araie M, 2011. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. *Exp Eye Res*; 93: 265–270.